Why Akebia Therapeutics Stock Is Plunging Today

Why Akebia Therapeutics Stock Is Plunging Today
Prosper Junior Bakiny, The Motley Fool
·2 min read

Akebia Therapeutics' total revenue of $56.7 million for its fourth quarter, ending Dec. 31, beat the consensus analyst estimate, which was $51.16 million. On the bottom line, Akebia Therapeutics reported a net loss of $87 million -- $0.60 per share -- compared to the net loss and net loss per share of $94.5 million and $0.79 respectively that it recorded during the fourth quarter of the previous fiscal year. On average, analysts expected the company's net loss per share to be $0.40.